Stock futures are surging after the Fed signaled interest rate cuts may begin as early as July.US Marketsread more
The billionaire investor believes the stock market is in a "zone of fair value" at current levels.Marketsread more
The Federal Reserve may be on its way to delivering a half-point interest rate cut next month, according to Goldman Sachs economists.Economyread more
However, Slack chief Stewart Butterfield says, "The broader world of email will stick around."Technologyread more
Crude oil prices jump on news of the attack, which Iran says happened over its territory.World Politicsread more
Apple is considering moving some production from China as it is expected release of its new iPhone line this fall, The Wall Street Journal reported.Technologyread more
Workplace messaging firm Slack is about to go public in a red-hot IPO market, but it's approach to going public--using a "direct listing"--is slightly different than an IPO.Trader Talk with Bob Pisaniread more
The yield on the benchmark 10-year Treasury note fell below 2% for the first time since November 2016 on Wednesday.Bondsread more
National Securities' Art Hogan sees the U.S.-China trade war as the market's biggest risk – not Fed policy.Trading Nationread more
The Philadelphia Federal Reserve's manufacturing gauge tumbled this month, solidifying the Fed's case for easier monetary policy.Economyread more
Declining traffic to Olive Garden, Darden's top restaurant chain, resulted in weaker-than-expected revenue for its fiscal fourth quarter.Restaurantsread more
It's that time again! The Lightning Round bell has rung, and Jim Cramer gives his take on a few favorite audience stocks:
Five Prime Therapeutics: "These antibody therapeutic stocks have about a dozen of them right now. They are at the epicenter of the blast zone. So what we are going to do is we are going to say don't buy until all the weak hands get out."
Isis Pharmaceuticals: "As I said last week...Isis hit a 52-week high last week and I expected that it would probably go down. Then everyone was free to take their gains because I was tired of defending it. My take is this: It's going to go even lower because it's part of the highest multiple speculative biotechs, but it will be a stock that I will like very much as the velocity of the decline wanes."
: "I think it is going to come under the category of speculative. For the next several weeks I expect speculative stocks will get hammered like they did last year at this time. Then we can come back to it, but I don't want you to buy it up on that spike."
: "I was going to suggest , because Priceline has a big business and that's another way to go. Ryanair is more of a pure play, and I like that concept. "
: "Digital home entertainment. That's a tough one...I'm not a big believer in the digital home theory, other than and that is a cult stock that is going to come down a bit.. might be a better place to go. "
: "Stay away. They've cleared up some of the accounting issues, but I really don't want to touch it. It just got kicked out of the and just doesn't have enough going for it. "
: "I think that's a very interesting situation...I think URI is doing quite well, and I think that this is the sweet spot for it. If that stock takes a hit because of the market, that's a great place to be. The fact that it held up so well today, what does that tell you? Strength! I like strength in this kind of market."
Read more from Mad Money with Jim Cramer
Cramer: The stocks that could trigger a rally
Cramer: Airline tech in focus after tragedy
: "Conoco is right. It's got that good yield and oil has bottomed at $43, and I think you buy Conoco."
: "That's a buy. I think that it is a sweet spot company."
: "I thought I would never say this, but Pfizer is an outright buy. It's a good place to be. Good yield, will make you a lot of moves. Smart, smart, smart and much smarter than it used to be."